A recent study has shown that a single dose of fibroblast growth factor (FGF) 1 into the central nervous system (CNS) of various mouse and rat models of type 2 diabetes results in profound and exceptionally long-lasting reductions in blood glucose. This work raises the possibility of truly revolutionary therapies for individuals with type 2 diabetes that target the brain FGF system.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A hindbrain inhibitory microcircuit mediates vagally-coordinated glucose regulation
Scientific Reports Open Access 25 February 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Scarlett, J.M. et al. Nat. Med. 22, 800–806 (2016).
Kliewer, S.A. & Mangelsdorf, D.J. Dig. Dis. 33, 327–331 (2015).
Raju, R. et al. J. Signal Transduct. 2014, 962962 (2014).
Beenken, A. & Mohammadi, M. Nat. Rev. Drug Discov. 8, 235–253 (2009).
Suh, J.M. et al. Nature 513, 436–439 (2014).
Jonker, J.W. et al. Nature 485, 391–394 (2012).
Sandoval, D., Cota, D. & Seeley, R.J. Annu. Rev. Physiol. 70, 513–535 (2008).
Mighiu, P.I. et al. Nat. Med. 19, 766–772 (2013).
Pinto, S. et al. Science 304, 110–115 (2004).
Dietrich, M.O. et al. Nat. Neurosci. 15, 1108–1110 (2012).
Goodman, T. & Hajihosseini, M.K. Front. Neurosci. 9, 387 (2015).
Bernard, C. Leçons de Physiologie Expérimental Appliqués à la Médecine: 1 Faites au Collége de France (J.B. Baillière et Fils, Paris, 1854).
Acknowledgements
D.A.S. has received research support from Novo Nordisk, Ethicon, Janssen and Boehringer Ingelheim. R.J.S. has received research support from Novo Nordisk, Ethicon, Janssen, Sanofi and Boehringer Ingelheim. R.J.S. has also served as a paid consultant for Novo Nordisk, Ethicon, Janssen, Novartis, Nestle, Daiichi Sankyo and Takeda.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Seeley, R., Sandoval, D. Targeting the brain as a cure for type 2 diabetes. Nat Med 22, 709–711 (2016). https://doi.org/10.1038/nm.4137
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4137
This article is cited by
-
A hindbrain inhibitory microcircuit mediates vagally-coordinated glucose regulation
Scientific Reports (2019)
-
The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes
Current Diabetes Reports (2017)